Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Otros (Other)

Towards precision prognostication and personalized therapeutics through proteomics

  • Santamaría Martínez, Enrique
Next-generation proteomics has allowed the implementation of biomedical proteome research to uncover disease-affected protein expression profiles. It has also enabled the determination of protein localization, protein interactomes, posttranslational modifications and protein dysfunction in human diseases. Many pillars in personalized medicine, such as diagnostic improvements, drug screening, systems biology or bioinformatics, require the generation of quantitatively consistent proteomics data from translational animal models to human biospecimens to fill the information gap, making omics analysis actionable from a clinical perspective [1-3]. This Special Issue received multiple submissions, of which five original articles were accepted for publication. These contributions cover different phases of precision medicine in the context of proteomics: (i) discovery and quantitation of potential biomarker candidates (three articles), (ii) the proteostatic modulation and mechanisms of action of pharmacological compounds (one article) and (iii) the characterization of posttranslational modifications (one article)., This work was funded by grants from the Spanish Ministry of Science, Innovation and Universities (Ref. PID2019-110356RB-I00/AEI/10.13039/501100011033) and the Department of Economic and Business Development from Government of Navarra (Ref. 0011-1411-2020-000028).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Improvement of cognitive function in wild-type and Alzheimer's disease mouse models by the immunomodulatory properties of menthol inhalation or by depletion of T regulatory cells

  • Casares, Noelia
  • Alfaro Larraya, María
  • Cuadrado-Tejedor, Mar
  • Lasarte-Cía, Aritz
  • Navarro Negredo, Flor
  • Vivas, Isabel
  • Espelosín, María
  • Cartas Cejudo, Paz
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • García-Osta, Ana
  • Lasarte, Juan José
A complex network of interactions exists between the olfactory, immune and central nervous systems. In this work we intend to investigate this connection through the use of an immunostimulatory odorant like menthol, analyzing its impact on the immune system and the cognitive capacity in healthy and Alzheimer’s Disease Mouse Models. We first found that repeated short exposures to menthol odor enhanced the immune response against ovalbumin immunization. Menthol inhalation also improved the cognitive capacity of immunocompetent mice but not in immunodeficient NSG mice, which exhibited very poor fear-conditioning. This improvement was associated with a downregulation of IL-1β and IL-6 mRNA in the brain´s prefrontal cortex, and it was impaired by anosmia induction with methimazole. Exposure to menthol for 6 months (1 week per month) prevented the cognitive impairment observed in the APP/PS1 mouse model of Alzheimer. Besides, this improvement was also observed by the depletion or inhibition of T regulatory cells. Treg depletion also improved the cognitive capacity of the APPNL-G-F/NL-G-F Alzheimer´s mouse model. In all cases, the improvement in learning capacity was associated with a downregulation of IL-1β mRNA. Blockade of the IL-1 receptor with anakinra resulted in a significant increase in cognitive capacity in healthy mice as well as in the APP/PS1 model of Alzheimer´s disease. These data suggest an association between the immunomodulatory capacity of smells and their impact on the cognitive functions of the animals, highlighting the potential of odors and immune modulators as therapeutic agents for CNS-related diseases., This work was supported by a grant from the Ministry of Science and Innovation (PID2021-128283OA-I00 financed by MCIN/ AEI /10.13039/501100011033 and by FEDER A way of making Europe and PID2019-104921RB-I00), Department of Economic and Business Development from the Government of Navarra (INNOLFACT project; Ref. 0011-1411-2020-000028) and Explora grant from Ministry of Economy and Competitiveness, (SAF2013-50067-EXP to JL).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Tesis doctoral (DoctoralThesis)

Decoding molecular olfactory alterations in neurodegeneration: sex differences and drug repurposing strategies in Alzheimer’s and Parkinson’s diseases

  • Cartas Cejudo, Paz
La disfunción olfativa es una característica temprana y común de las enfermedades neurodegenerativas (EN), particularmente de la enfermedad de Alzheimer (EA) y la enfermedad de Parkinson (EP), donde los cambios patológicos en las regiones de procesamiento olfativo, como el tracto olfativo (TO), contribuyen a los déficits en el sentido del olfato. Esta tesis tiene como objetivo explorar los mecanismos moleculares subyacentes a estos trastornos, utilizando proteómica de alto rendimiento para analizar muestras post-mortem del TO de sujetos con EA, EP y controles. El análisis de expresión proteica diferencial reveló alteraciones proteómicas significativas tanto en la EA como en la EP, con variaciones dependientes del sexo observadas, particularmente en la expresión de sirtuinas (SIRTs). De manera notable, las mujeres mostraron una disfunción proteómica más grave en comparación con los hombres, independientemente de la enfermedad, con patrones alterados de acetilación de proteínas en regiones olfativas clave en el cerebro. Además, establecimos un flujo de trabajo utilizando firmas ómicas olfativas y del tronco encefálico en un enfoque computacional, Connectivity Map (CMap), con el objetivo de obtener posibles dianas para el reposicionamiento de fármacos en EA y EP. Además, varias clases farmacológicas parecían ser candidatas potenciales para restaurar las firmas ómicas alteradas. La validación in vitro confirma que varios de los inhibidores propuestos ejercieron efectos neuroprotectores, reduciendo el daño por estímulos neuropatológicos y la toxicidad por estrés oxidativo. Estos hallazgos subrayan el valor de la proteómica olfativa para entender los mecanismos moleculares específicos del sexo en la EA y la EP, y sugieren que las firmas ómicas podrían servir como plantilla para desarrollar nuevas estrategias terapéuticas frente a los síndromes neurológicos., Olfactory dysfunction is an early and common feature of neurodegenerative diseases (NDs), particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD), where pathological changes in olfactory processing regions, such as the olfactory tract (OT) contribute to deficits in smell. This thesis aimed to explore the molecular mechanisms underlying these impairments, using high-throughput proteomics to analyze post-mortem OT samples from AD, PD, and control subjects. Differential protein expression analysis revealed significant proteomic alterations in both AD and PD, with sex-dependent variations observed, particularly in the expression of sirtuins (SIRTs). Notably women showed more severe proteomic dysregulation compared to men, regardless of the disease, with altered protein acetylation patterns in key olfactory brain regions. Moreover, we established a workflow using olfactory and brainstem omics signatures in a computational approach, Connectivity Map (CMap), with the aim of obtaining potential targets for drug repurposing in AD and PD. Furthermore, various pharmacological classes seemed to be potential candidates to restore disrupted omics signatures. In vitro validation confirmed that several of the proposed inhibitors exerted neuroprotective effects, reducing damage from neuropathological insults and oxidative stress toxicity. These findings underscore the value of olfactory proteomics in understanding sex-specific molecular mechanisms in AD and PD and suggest that omics signatures could serve as a template for developing novel therapeutic strategies against neurological syndromes., Ayudas y financiaciones que han permitido el desarrollo de esta tesis: Referencia: 0011-1411-2020-000028. Entidad: Departamento de Desarrollo Económico y Empresarial (Estratégicos S3) del Gobierno de Navarra. Convocatoria 2020 de ayudas a proyectos estratégicos de I+D. Título: INNOLFACT. Implementación de medicina de precisión olfatoria y desarrollo de terapias nasales inmunomoduladores en envejecimiento y neurodegeneración. Duración: 2020-2022; Referencia: 0011-1411-2023-000028. Entidad: Departamento de Desarrollo Económico y Empresarial (Estratégicos S4) del Gobierno de Navarra. Convocatoria 2023-2026 de ayudas a proyectos estratégicos de I+D. Título: INNOLFACT 2.0: Combinación de Inteligencia Artificial y Reposicionamiento de Fármacos en Medicina de Precisión Olfatoria Duración: 2023-2025; Referencia: PID2023-152593OB-I00. Entidad: AEI. Proyectos de Generación de Conocimiento» del Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia, en el marco del Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023. Título: INTERFERENCIA ENTRE LA ACETILACION Y LA FOSFORILACION EN LA ENFERMEDAD DE ALZHEIMER: PAPEL DE LAS SIRTUINAS 3 Y 7 EN NEURODEGENERACION OLFATORIA., Programa de Doctorado en Ciencias de la Salud (RD 99/2011), Osasun Zientzietako Doktoretza Programa (ED 99/2011)
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Proteostatic modulation in brain aging without associated Alzheimer's disease-and age-related neuropathological changes

  • Andrés Benito, Pol
  • Íñigo-Marco, Ignacio
  • Brullas, Marta
  • Carmona, Margarita
  • Río, José Antonio del
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Povedano, Mónica
  • Ferrer, Isidro
Aims: (Phospho)proteomics of old-aged subjects without cognitive or behavioral symptoms, and without ADneuropathological changes and lacking any other neurodegenerative alteration will increase understanding about the physiological state of human brain aging without associate neurological deficits and neuropathological lesions. Methods: (Phospho)proteomics using conventional label-free- and SWATH-MS (Sequential window acquisition of all theoretical fragment ion spectra mass spectrometry) has been assessed in the frontal cortex (FC) of individuals without NFTs, senile plaques (SPs) and age-related co-morbidities classified by age (years) in four groups; group 1 (young, 30–44); group 2 (middle-aged: MA, 45-52); group 3 (early-elderly, 64–70); and group 4 (late-elderly, 75–85). Results: Protein levels and deregulated protein phosphorylation linked to similar biological terms/functions, but involving different individual proteins, are found in FC with age. The modified expression occurs in cytoskeleton proteins, membranes, synapses, vesicles, myelin, membrane transport and ion channels, DNA and RNA metabolism, ubiquitin-proteasome-system (UPS), kinases and phosphatases, fatty acid metabolism, and mitochondria. Dysregulated phosphoproteins are associated with the cytoskeleton, including microfilaments, actin-binding proteins, intermediate filaments of neurons and glial cells, and microtubules; membrane proteins, synapses, and dense core vesicles; kinases and phosphatases; proteins linked to DNA and RNA; members of the UPS; GTPase regulation; inflammation; and lipid metabolism. Noteworthy, protein levels of large clusters of hierarchically-related protein expression levels are stable until 70. However, protein levels of components of cell membranes, vesicles and synapses, RNA modulation, and cellular structures (including tau and tubulin filaments) are markedly altered from the age of 75. Similarly, marked modifications occur in the larger phosphoprotein clusters involving cytoskeleton and neuronal structures, membrane stabilization, and kinase regulation in the late elderly. Conclusions: Present findings may increase understanding of human brain proteostasis modifications in the elderly in the subpopulation of individuals not having AD neuropathological change and any other neurodegenerative change in any telencephalon region., The project leading to these results received funding from the “la Caixa” Foundation (ID 100010434) under the agreement LCF/PR/HR19/52160007, HR18-00452 to IF and JAdR. We thank CERCA Programme/Generalitat de Catalunya for institutional support. The Proteomics Platform of Navarrabiomed is a member of Proteored (PRB3-ISCIII) and is supported by grant PT17/0019/009 to JFI, of the PE I+D+I 2013–2016 funded by ISCIII and FEDER. Parts of this work were funded by a grant from the Spanish Ministry of Science Innovation and Universities (Ref. PID2019-110356RB-I00) to JFI and ES, and the Department of Economic and Business Development of the Government of Navarra (Ref. 0011- 1411-2020-000028) to ES.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Involvement of glucosamine 6 phosphate isomerase 2 (GNPDA2) overproduction in beta-amyloid- and Tau P301L-driven pathomechanisms

  • Lachén Montes, Mercedes
  • Cartas Cejudo, Paz
  • Cortés, Adriana
  • Anaya-Cubero, Elena
  • Peral, Erika
  • Ausín, Karina
  • Díaz-Peña, Ramón
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
Alzheimer’s disease (AD) is a neurodegenerative olfactory disorder affecting millions of people worldwide. Alterations in the hexosamine- or glucose-related pathways have been described through AD progression. Specifically, an alteration in glucosamine 6 phosphate isomerase 2 (GNPDA2) protein levels has been observed in olfactory areas of AD subjects. However, the biological role of GNPDA2 in neurodegeneration remains unknown. Using mass spectrometry, multiple GNPDA2 interactors were identified in human nasal epithelial cells (NECs) mainly involved in intraciliary transport. Moreover, GNPDA2 overexpression induced an increment in NEC proliferation rates, accompanied by transcriptomic alterations in Type II interferon signaling or cellular stress responses. In contrast, the presence of beta-amyloid or mutated Tau-P301L in GNPDA2-overexpressing NECs induced a slowdown in the proliferative capacity in parallel with a disruption in protein processing. The proteomic characterization of Tau-P301L transgenic zebrafish embryos demonstrated that GNPDA2 overexpression interfered with collagen biosynthesis and RNA/protein processing, without inducing additional changes in axonal outgrowth defects or neuronal cell death. In humans, a significant increase in serum GNPDA2 levels was observed across multiple neurological proteinopathies (AD, Lewy body dementia, progressive supranuclear palsy, mixed dementia and amyotrophic lateral sclerosis) (n = 215). These data shed new light on GNPDA2-dependent mechanisms associated with the neurodegenerative process beyond the hexosamine route., This work was funded by grants from the Spanish Ministry of Science, Innovation and Universities (Ref. PID2019-110356RB-I00/AEI/10.13039/501100011033) to J.F.-I. and E.S. and the Department of Economic and Business Development from Government of Navarra (Ref. 0011-1411-2020-000028 and 0011-1411-2023-000028 to E.S.).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Sex-divergent effects on the NAD+-dependent deacetylase sirtuin signaling across the olfactory-entorhinal-amygdaloid axis in Alzheimer's and Parkinson's diseases

  • Cartas Cejudo, Paz
  • Lachén Montes, Mercedes
  • Ferrer, Isidro
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
Background Smell impairment is one of the earliest features in Alzheimer’s (AD) and Parkinson’s diseases (PD). Due to sex diferences exist in terms of smell and olfactory structures as well as in the prevalence and manifestation of both neurological syndromes, we have applied olfactory proteomics to favor the discovery of novel sex-biased physio-pathological mechanisms and potential therapeutic targets associated with olfactory dysfunction. Methods SWATH-MS (sequential window acquisition of all theoretical fragment ion spectra mass spectrometry) and bioinformatic workfows were applied in 57 post-mortem olfactory tracts (OT) derived from controls with no known neurological history (n=6F/11M), AD (n=4F/13M) and PD (n=7F/16M) subjects. Complementary molecular analyses by Western-blotting were performed in the olfactory bulb (OB), entorhinal cortex (EC) and amygdala areas. Results 327 and 151 OT diferentially expressed proteins (DEPs) were observed in AD women and AD men, respec‑ tively (35 DEPs in common). With respect to PD, 198 DEPs were identifed in PD women, whereas 95 DEPs were detected in PD men (20 DEPs in common). This proteome dyshomeostasis induced a disruption in OT protein interac‑ tion networks and widespread sex-dependent pathway perturbations in a disease-specifc manner, among them Sirtuin (SIRT) signaling. SIRT1, SIRT2, SIRT3 and SIRT5 protein levels unveiled a tangled expression profle across the olfactory–entorhinal–amygdaloid axis, evidencing disease-, sex- and brain structure-dependent changes in olfactory protein acetylation. Conclusions Alteration in the OT proteostasis was more severe in AD than in PD. Moreover, protein expression changes were more abundant in women than men independent of the neurological syndrome. Mechanistically, the tangled SIRT profle observed across the olfactory pathway-associated brain regions in AD and PD indicates difer‑ ential NAD (+)-dependent deacetylase mechanisms between women and men. All these data shed new light on diferential olfactory mechanisms across AD and PD, pointing out that the evaluation of the feasibility of emerging sirtuin-based therapies against neurodegenerative diseases should be considered with caution, including further sex dimension analyses in vivo and in clinical studies., The Proteomics Platform of Navarrabiomed was member of Proteored (PRB3-ISCIII) supported by grant PT17/0019/009, of the PE I+D+I 2013–2016 funded by ISCIII and FEDER. The Clinical Neuroproteomics Unit of Navarrabiomed is member of the Global Consortium for Chemosensory Research (GCCR) and the Spanish Olfactory Network (ROE) (supported by grant RED2018-102662-T funded by Spanish Ministry of Science and Innovation). This work was funded by grants from the Spanish Ministry of Science, Innovation and Universities (Ref. PID2019-110356RB-I00/AEI/10.13039/501100011033). to J.F.-I. and E.S.) and the Department of Economic and Business Development from Government of Navarra (Ref. 0011-1411-2020-000028 to E.S.). PC-C was supported by a predoctoral fellowship from the Public University of Navarra (UPNA).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Deregulated transcription and proteostasis in adult mapt knockout mouse

  • Andrés Benito, Pol
  • Flores, África
  • Busquet-Areny, Sara
  • Carmona, Margarita
  • Ausín, Karina
  • Cartas Cejudo, Paz
  • Lachén Montes, Mercedes
  • Río, José Antonio del
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Ferrer, Isidro
Transcriptomics and phosphoproteomics were carried out in the cerebral cortex of B6.Cg-Mapttm1(EGFP)Klt (tau knockout: tau-KO) and wild-type (WT) 12 month-old mice to learn about the effects of tau ablation. Compared with WT mice, tau-KO mice displayed reduced anxiety-like behavior and lower fear expression induced by aversive conditioning, whereas recognition memory remained unaltered. Cortical transcriptomic analysis revealed 69 downregulated and 105 upregulated genes in tau-KO mice, corresponding to synaptic structures, neuron cytoskeleton and transport, and extracellular matrix components. RT-qPCR validated increased mRNA levels of col6a4, gabrq, gad1, grm5, grip2, map2, rab8a, tubb3, wnt16, and an absence of map1a in tau-KO mice compared with WT mice. A few proteins were assessed with Western blotting to compare mRNA expression with corresponding protein levels. Map1a mRNA and protein levels decreased. However, ¿-tubulin III and GAD1 protein levels were reduced in tau-KO mice. Cortical phosphoproteomics revealed 121 hypophosphorylated and 98 hyperphosphorylated proteins in tau-KO mice. Deregulated phosphoproteins were categorized into cytoskeletal (n = 45) and membrane proteins, including proteins of the synapses and vesicles, myelin proteins, and proteins linked to membrane transport and ion channels (n = 84), proteins related to DNA and RNA metabolism (n = 36), proteins connected to the ubiquitin-proteasome system (UPS) (n = 7), proteins with kinase or phosphatase activity (n = 21), and 22 other proteins related to variegated pathways such as metabolic pathways, growth factors, or mitochondrial function or structure. The present observations reveal a complex altered brain transcriptome and phosphoproteome in tau-KO mice with only mild behavioral alterations., The project leading to these results received funding from the “la Caixa” Foundation (ID 100010434) under the agreements LCF/PR/HR19/52160007, HR18-00452 to IF. We thank the CERCA Programme/Generalitat de Catalunya for institutional support. The Proteomics Platform of Navarrabiomed is a member of Proteored (PRB3-ISCIII), supported by grant PT17/0019/009 to J.F.-I. of the PE I + D + I 2013-2016 funded by ISCIII and FEDER. This work was funded by a grant from the Spanish Ministry of Science, Innovation, and Universities (Ref. PID2019-110356RB-I00) to J.F.-I. and E.S. and the Department of Economic and Business Development from the Government of Navarra (Ref. 0011-1411-2020-000028) to E.S.